Related Experiment Video
Updated: May 8, 2026
07:13
Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
AT1 antagonists: a patent review (2008 - 2012)
Thomas Mavromoustakos1, George Agelis, Serdar Durdagi
1University of Athens, Department of Chemistry , Panepistimiopolis Zografou 15771, Athens , Greece tmavrom@chem.uoa.gr.
Expert Opinion on Therapeutic Patents
|August 24, 2013
Summary
New research on
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Drug Discovery
Background:
- The renin-angiotensin system (RAS) plays a crucial role in regulating blood pressure.
- Angiotensin II AT1 receptor antagonists, known as 'Sartans', have been used for hypertension treatment for two decades.
- Structural modifications of Sartans can lead to multi-target properties and novel therapeutic applications.
Purpose of the Study:
- To review key patents from 2008-2012 concerning Angiotensin II AT1 receptor antagonists.
- To identify emerging trends and potential new discoveries in the field of Sartan-based therapeutics.
- To highlight advancements in drug design and formulation for RAS-related diseases.
Main Methods:
- Patent analysis of literature published between 2008 and 2012.
- Review of novel structural features and synthetic compounds.
- Investigation of new formulation strategies and combination therapies.
Main Results:
- Patents reveal ongoing innovation in Sartan development.
- New structural modifications offer potential for enhanced efficacy and multi-target actions.
- Advancements in drug delivery systems like cyclodextrins, polymers, and liposomes are evident.
Conclusions:
- Significant opportunities exist for novel discoveries in Angiotensin II AT1 receptor antagonist research.
- Further exploration of structural diversity and multi-target approaches is warranted.
- New formulations and rational drug design for combination therapies hold promise for treating RAS-related diseases.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...